JP2014520793A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520793A5 JP2014520793A5 JP2014517980A JP2014517980A JP2014520793A5 JP 2014520793 A5 JP2014520793 A5 JP 2014520793A5 JP 2014517980 A JP2014517980 A JP 2014517980A JP 2014517980 A JP2014517980 A JP 2014517980A JP 2014520793 A5 JP2014520793 A5 JP 2014520793A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methyl
- pyrrolo
- fluoro
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 13
- 206010052779 Transplant rejections Diseases 0.000 claims description 13
- 230000001404 mediated effect Effects 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 7
- 208000024376 chronic urticaria Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 208000023328 Basedow disease Diseases 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- 208000015023 Graves' disease Diseases 0.000 claims description 5
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 5
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 5
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 201000011152 Pemphigus Diseases 0.000 claims description 5
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 5
- 230000001086 cytosolic effect Effects 0.000 claims description 5
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 5
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 5
- 206010028417 myasthenia gravis Diseases 0.000 claims description 5
- 208000025113 myeloid leukemia Diseases 0.000 claims description 5
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 206010043554 thrombocytopenia Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 230000009424 thromboembolic effect Effects 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 35
- 239000001257 hydrogen Substances 0.000 claims 35
- 229910052736 halogen Chemical group 0.000 claims 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 21
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims 15
- 150000002367 halogens Chemical group 0.000 claims 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 13
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 150000002431 hydrogen Chemical group 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 9
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- YWPMKTWUFVOFPL-UHFFFAOYSA-N 3,4-dihydro-2h-isoquinolin-1-one Chemical group C1=CC=C2C(=O)NCCC2=C1 YWPMKTWUFVOFPL-UHFFFAOYSA-N 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical group O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims 3
- ZAUVEVHTVQJRTN-UHFFFAOYSA-N 4-[4-[3-[(4-acetylbenzoyl)amino]-5-fluoro-2-methylphenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=CC(=CC=3)C(C)=O)C=C(F)C=2)C)=C1 ZAUVEVHTVQJRTN-UHFFFAOYSA-N 0.000 claims 2
- UZQDYTBAPMZXKM-UHFFFAOYSA-N 4-cyclopropyl-n-[5-fluoro-2-methyl-3-[6-[1-(pyrrolidine-1-carbonyl)-3,6-dihydro-2h-pyridin-4-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]benzamide Chemical compound C1=C(F)C=C(C=2C=3C=C(NC=3N=CN=2)C=2CCN(CC=2)C(=O)N2CCCC2)C(C)=C1NC(=O)C(C=C1)=CC=C1C1CC1 UZQDYTBAPMZXKM-UHFFFAOYSA-N 0.000 claims 2
- CKEMXFLXVHEYLO-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]benzamide Chemical compound C1=C(F)C=C(C=2C=3C=C(NC=3N=CN=2)C=2CCC3(CC=2)OCCO3)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 CKEMXFLXVHEYLO-UHFFFAOYSA-N 0.000 claims 2
- ZWWQAKIQAPSJRV-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-(3,6-dihydro-2h-thiopyran-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]benzamide Chemical compound C1=C(F)C=C(C=2C=3C=C(NC=3N=CN=2)C=2CCSCC=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 ZWWQAKIQAPSJRV-UHFFFAOYSA-N 0.000 claims 2
- DEDSPQBYYGKANF-UHFFFAOYSA-N 4-tert-butyl-n-[5-fluoro-3-[6-(4-hydroxycyclohexen-1-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-2-methylphenyl]benzamide Chemical compound C1=C(F)C=C(C=2C=3C=C(NC=3N=CN=2)C=2CCC(O)CC=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 DEDSPQBYYGKANF-UHFFFAOYSA-N 0.000 claims 2
- RJHGOPBGEROWRB-UHFFFAOYSA-N [2-[4-[4-[3-[(4-cyclopropylbenzoyl)amino]-5-fluoro-2-methylphenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl] acetate Chemical compound C1N(C(=O)COC(=O)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=CC(=CC=3)C3CC3)C=C(F)C=2)C)=C1 RJHGOPBGEROWRB-UHFFFAOYSA-N 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- BXZGCFXOZWMQQC-UHFFFAOYSA-N n-[3-[6-(3,6-dihydro-2h-pyran-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-2-(hydroxymethyl)phenyl]-2-fluoro-4-(2-hydroxypropan-2-yl)benzamide Chemical compound FC1=CC(C(C)(O)C)=CC=C1C(=O)NC1=CC=CC(C=2C=3C=C(NC=3N=CN=2)C=2CCOCC=2)=C1CO BXZGCFXOZWMQQC-UHFFFAOYSA-N 0.000 claims 2
- PSLXNEVDCJSLEL-UHFFFAOYSA-N n-[3-[6-(3,6-dihydro-2h-pyran-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-2-fluoro-4-(2-hydroxypropan-2-yl)benzamide Chemical compound C1=C(F)C=C(C=2C=3C=C(NC=3N=CN=2)C=2CCOCC=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)O)C=C1F PSLXNEVDCJSLEL-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000006420 1-fluorocyclopropyl group Chemical group [H]C1([H])C([H])([H])C1(F)* 0.000 claims 1
- SQWBWWKSKVGXAC-UHFFFAOYSA-N 1-methylpyrrolo[2,3-b]pyridine-6-carboxylic acid Chemical compound C1=C(C(O)=O)N=C2N(C)C=CC2=C1 SQWBWWKSKVGXAC-UHFFFAOYSA-N 0.000 claims 1
- SZMBVFYZJRXDCM-UHFFFAOYSA-N 4-[4-[2-(hydroxymethyl)-3-[6-(2-hydroxypropan-2-yl)-1-oxo-3,4-dihydroisoquinolin-2-yl]phenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(N3C(C4=CC=C(C=C4CC3)C(C)(C)O)=O)C=CC=2)CO)=C1 SZMBVFYZJRXDCM-UHFFFAOYSA-N 0.000 claims 1
- VDPHWIWWROGXAO-UHFFFAOYSA-N 4-[4-[3-(6-tert-butyl-1-oxo-3,4-dihydroisoquinolin-2-yl)-2-(hydroxymethyl)phenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(N3C(C4=CC=C(C=C4CC3)C(C)(C)C)=O)C=CC=2)CO)=C1 VDPHWIWWROGXAO-UHFFFAOYSA-N 0.000 claims 1
- JSHGXUDFCKQNOV-UHFFFAOYSA-N 4-[4-[3-[(4-cyclopropylbenzoyl)amino]-2-(hydroxymethyl)phenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=CC(=CC=3)C3CC3)C=CC=2)CO)=C1 JSHGXUDFCKQNOV-UHFFFAOYSA-N 0.000 claims 1
- GZABPYMEPKWSAR-UHFFFAOYSA-N 4-[4-[3-[(4-cyclopropylbenzoyl)amino]-4-fluorophenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C=C(NC(=O)C=3C=CC(=CC=3)C3CC3)C(F)=CC=2)=C1 GZABPYMEPKWSAR-UHFFFAOYSA-N 0.000 claims 1
- IIYOOOONDUTPRD-UHFFFAOYSA-N 4-[4-[3-[(4-tert-butylbenzoyl)amino]-5-fluoro-2-methylphenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=CC(=CC=3)C(C)(C)C)C=C(F)C=2)C)=C1 IIYOOOONDUTPRD-UHFFFAOYSA-N 0.000 claims 1
- YEUUOSNTDSZKQF-UHFFFAOYSA-N 4-[4-[3-[[2-fluoro-4-(2-hydroxypropan-2-yl)benzoyl]amino]-2-(hydroxymethyl)phenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C(=CC(=CC=3)C(C)(C)O)F)C=CC=2)CO)=C1 YEUUOSNTDSZKQF-UHFFFAOYSA-N 0.000 claims 1
- JWXICKMBHDHSJV-UHFFFAOYSA-N 4-[4-[3-[[4-(dimethylamino)benzoyl]amino]-5-fluoro-2-methylphenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=CC(=CC=3)N(C)C)C=C(F)C=2)C)=C1 JWXICKMBHDHSJV-UHFFFAOYSA-N 0.000 claims 1
- LJCBNGBBWDIUJW-UHFFFAOYSA-N 4-[4-[3-[benzoyl(prop-1-en-2-yl)amino]-5-fluoro-2-methylphenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(N(C(C)=C)C(=O)C=3C=CC=CC=3)C=C(F)C=2)C)=C1 LJCBNGBBWDIUJW-UHFFFAOYSA-N 0.000 claims 1
- WMTYXEKVXXLDOO-UHFFFAOYSA-N 4-[4-[4-fluoro-2-methyl-3-[[3-[(2-methylpropan-2-yl)oxy]azetidine-1-carbonyl]amino]phenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)N3CC(C3)OC(C)(C)C)C(F)=CC=2)C)=C1 WMTYXEKVXXLDOO-UHFFFAOYSA-N 0.000 claims 1
- IJUNVOJIYZFJBT-UHFFFAOYSA-N 4-[4-[4-fluoro-3-[[3-[(2-methylpropan-2-yl)oxy]azetidine-1-carbonyl]amino]phenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C=C(NC(=O)N3CC(C3)OC(C)(C)C)C(F)=CC=2)=C1 IJUNVOJIYZFJBT-UHFFFAOYSA-N 0.000 claims 1
- ZMZQAZFJKRCEGJ-UHFFFAOYSA-N 4-[4-[5-fluoro-2-methyl-3-[(4-piperidin-1-ylbenzoyl)amino]phenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=CC(=CC=3)N3CCCCC3)C=C(F)C=2)C)=C1 ZMZQAZFJKRCEGJ-UHFFFAOYSA-N 0.000 claims 1
- AWMQABFYTUZIJL-UHFFFAOYSA-N 4-[4-[5-fluoro-2-methyl-3-[(4-propan-2-yloxybenzoyl)amino]phenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)NC1=CC(F)=CC(C=2C=3C=C(NC=3N=CN=2)C=2CCN(CC=2)C(=O)N(C)C)=C1C AWMQABFYTUZIJL-UHFFFAOYSA-N 0.000 claims 1
- WLNMTYVVPHKNPT-UHFFFAOYSA-N 4-[4-[5-fluoro-2-methyl-3-[[3-[(2-methylpropan-2-yl)oxy]azetidine-1-carbonyl]amino]phenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)N3CC(C3)OC(C)(C)C)C=C(F)C=2)C)=C1 WLNMTYVVPHKNPT-UHFFFAOYSA-N 0.000 claims 1
- YAOURPFQCBCOGE-UHFFFAOYSA-N 4-[4-[5-fluoro-2-methyl-3-[[4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzoyl]amino]phenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=CC(=CC=3)C(C)(O)C(F)(F)F)C=C(F)C=2)C)=C1 YAOURPFQCBCOGE-UHFFFAOYSA-N 0.000 claims 1
- IEGRMNYULFKAKP-UHFFFAOYSA-N 4-[4-[5-fluoro-2-methyl-3-[[4-[1-(trifluoromethyl)cyclopropyl]benzoyl]amino]phenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=CC(=CC=3)C3(CC3)C(F)(F)F)C=C(F)C=2)C)=C1 IEGRMNYULFKAKP-UHFFFAOYSA-N 0.000 claims 1
- MLKDBPSLDGNZKN-UHFFFAOYSA-N 4-[4-[5-fluoro-3-[[2-fluoro-4-(2-hydroxypropan-2-yl)benzoyl]amino]-2-methylphenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C(=CC(=CC=3)C(C)(C)O)F)C=C(F)C=2)C)=C1 MLKDBPSLDGNZKN-UHFFFAOYSA-N 0.000 claims 1
- YYDRDORQKKYAEN-UHFFFAOYSA-N 4-[4-[5-fluoro-3-[[3-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)azetidine-1-carbonyl]amino]-2-methylphenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid Chemical compound FC=1C=C(C(=C(C=1)C=1C2=C(N=CN=1)NC(=C2)C=1CCN(CC=1)C(=O)O)C)NC(=O)N1CC(C1)OC(C(F)(F)F)C(F)(F)F YYDRDORQKKYAEN-UHFFFAOYSA-N 0.000 claims 1
- ZMMYFCIEQJSJGU-UHFFFAOYSA-N 4-[4-[5-fluoro-3-[[4-(1-hydroxy-2-methylpropan-2-yl)benzoyl]amino]-2-methylphenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=CC(=CC=3)C(C)(C)CO)C=C(F)C=2)C)=C1 ZMMYFCIEQJSJGU-UHFFFAOYSA-N 0.000 claims 1
- PFBLKWQTZFUGHL-UHFFFAOYSA-N 4-[4-[5-fluoro-3-[[4-(1-methoxy-2-methylpropan-2-yl)benzoyl]amino]-2-methylphenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1=CC(C(C)(C)COC)=CC=C1C(=O)NC1=CC(F)=CC(C=2C=3C=C(NC=3N=CN=2)C=2CCN(CC=2)C(=O)N(C)C)=C1C PFBLKWQTZFUGHL-UHFFFAOYSA-N 0.000 claims 1
- RXTLGQQWYGOUNM-UHFFFAOYSA-N 4-[4-[5-fluoro-3-[[4-(2-methoxypropan-2-yl)benzoyl]amino]-2-methylphenyl]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]-n,n-dimethyl-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1=CC(C(C)(C)OC)=CC=C1C(=O)NC1=CC(F)=CC(C=2C=3C=C(NC=3N=CN=2)C=2CCN(CC=2)C(=O)N(C)C)=C1C RXTLGQQWYGOUNM-UHFFFAOYSA-N 0.000 claims 1
- DZGTZCNHVYJJJU-UHFFFAOYSA-N 4-tert-butyl-n-[2-methyl-3-[6-(1-methylsulfonyl-3,6-dihydro-2h-pyridin-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]benzamide Chemical compound C1=CC=C(C=2C=3C=C(NC=3N=CN=2)C=2CCN(CC=2)S(C)(=O)=O)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 DZGTZCNHVYJJJU-UHFFFAOYSA-N 0.000 claims 1
- VRYZQIAOLUEBDN-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-2-(hydroxymethyl)phenyl]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NC1=CC=CC(C=2C=3C=C(NC=3N=CN=2)C=2CCC3(CC=2)OCCO3)=C1CO VRYZQIAOLUEBDN-UHFFFAOYSA-N 0.000 claims 1
- IEYMWIJHVRBMOB-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-2-methylphenyl]benzamide Chemical compound C1=CC=C(C=2C=3C=C(NC=3N=CN=2)C=2CCC3(CC=2)OCCO3)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 IEYMWIJHVRBMOB-UHFFFAOYSA-N 0.000 claims 1
- NECGVVPXSMRWLI-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-(3,6-dihydro-2h-pyran-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-2-(hydroxymethyl)phenyl]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NC1=CC=CC(C=2C=3C=C(NC=3N=CN=2)C=2CCOCC=2)=C1CO NECGVVPXSMRWLI-UHFFFAOYSA-N 0.000 claims 1
- SQYQDGSDELFVKF-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-(3,6-dihydro-2h-pyran-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]benzamide Chemical compound C1=C(F)C=C(C=2C=3C=C(NC=3N=CN=2)C=2CCOCC=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 SQYQDGSDELFVKF-UHFFFAOYSA-N 0.000 claims 1
- CSWAITWXEHUKRI-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-(3,6-dihydro-2h-thiopyran-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-2-methylphenyl]benzamide Chemical compound C1=CC=C(C=2C=3C=C(NC=3N=CN=2)C=2CCSCC=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 CSWAITWXEHUKRI-UHFFFAOYSA-N 0.000 claims 1
- DVAUUEDPFRNAMP-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-(4-hydroxycyclohexen-1-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-2-(hydroxymethyl)phenyl]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NC1=CC=CC(C=2C=3C=C(NC=3N=CN=2)C=2CCC(O)CC=2)=C1CO DVAUUEDPFRNAMP-UHFFFAOYSA-N 0.000 claims 1
- LOIGITGGOMQGLY-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-(4-hydroxycyclohexen-1-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-2-methylphenyl]benzamide Chemical compound C1=CC=C(C=2C=3C=C(NC=3N=CN=2)C=2CCC(O)CC=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 LOIGITGGOMQGLY-UHFFFAOYSA-N 0.000 claims 1
- WTMWKOGRGZGVBZ-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-[1-(2-fluoroacetyl)-3,6-dihydro-2h-pyridin-4-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-2-(hydroxymethyl)phenyl]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NC1=CC=CC(C=2C=3C=C(NC=3N=CN=2)C=2CCN(CC=2)C(=O)CF)=C1CO WTMWKOGRGZGVBZ-UHFFFAOYSA-N 0.000 claims 1
- QYSLVNJERLKIKQ-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-[1-(dimethylsulfamoyl)-3,6-dihydro-2h-pyridin-4-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]benzamide Chemical compound C1N(S(=O)(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=CC(=CC=3)C(C)(C)C)C=C(F)C=2)C)=C1 QYSLVNJERLKIKQ-UHFFFAOYSA-N 0.000 claims 1
- LJSAWTQFYUQZFA-UHFFFAOYSA-N 4-tert-butyl-n-[3-[6-[4-(dimethylamino)cyclohexen-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-2-(hydroxymethyl)phenyl]benzamide Chemical compound C1C(N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=CC(=CC=3)C(C)(C)C)C=CC=2)CO)=C1 LJSAWTQFYUQZFA-UHFFFAOYSA-N 0.000 claims 1
- CELWNVZCXQHXSO-UHFFFAOYSA-N 4-tert-butyl-n-[5-fluoro-2-methyl-3-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]benzamide Chemical compound C1=C(F)C=C(C=2C=3C=C(NC=3N=CN=2)C=2CCNCC=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 CELWNVZCXQHXSO-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000003976 azacycloalkanes Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- RUVAAIZLMCKMJR-UHFFFAOYSA-N n-[3-[6-(3,6-dihydro-2h-pyran-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-3-[(2-methylpropan-2-yl)oxy]azetidine-1-carboxamide Chemical compound C1=C(F)C=C(C=2C=3C=C(NC=3N=CN=2)C=2CCOCC=2)C(C)=C1NC(=O)N1CC(OC(C)(C)C)C1 RUVAAIZLMCKMJR-UHFFFAOYSA-N 0.000 claims 1
- CTGDAVDRLMDGCN-UHFFFAOYSA-N n-[3-[6-(3,6-dihydro-2h-pyran-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-(dimethylamino)benzamide Chemical compound C1=CC(N(C)C)=CC=C1C(=O)NC1=CC(F)=CC(C=2C=3C=C(NC=3N=CN=2)C=2CCOCC=2)=C1C CTGDAVDRLMDGCN-UHFFFAOYSA-N 0.000 claims 1
- ZLCGCPOJUAWPGO-UHFFFAOYSA-N n-[3-[6-[1-(2-cyanoacetyl)-3,6-dihydro-2h-pyridin-4-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropylbenzamide Chemical compound C1=C(F)C=C(C=2C=3C=C(NC=3N=CN=2)C=2CCN(CC=2)C(=O)CC#N)C(C)=C1NC(=O)C(C=C1)=CC=C1C1CC1 ZLCGCPOJUAWPGO-UHFFFAOYSA-N 0.000 claims 1
- XHIDLRFQSGVWEP-UHFFFAOYSA-N n-[3-[6-[1-(dimethylcarbamoyl)-3,6-dihydro-2h-pyridin-4-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-3-methyl-1h-indole-6-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)C=3C=C4NC=C(C)C4=CC=3)C=C(F)C=2)C)=C1 XHIDLRFQSGVWEP-UHFFFAOYSA-N 0.000 claims 1
- CQYJSPQAOHYHKO-UHFFFAOYSA-N n-[3-[6-[1-(dimethylcarbamoyl)-3,6-dihydro-2h-pyridin-4-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-5-fluoro-1,3-dihydroisoindole-2-carboxamide Chemical compound C1N(C(=O)N(C)C)CCC(C=2NC3=NC=NC(=C3C=2)C=2C(=C(NC(=O)N3CC4=CC(F)=CC=C4C3)C=C(F)C=2)C)=C1 CQYJSPQAOHYHKO-UHFFFAOYSA-N 0.000 claims 1
- SCGWVZNPYKESGN-UHFFFAOYSA-N n-[5-fluoro-2-methyl-3-[6-[1-(pyrrolidine-1-carbonyl)-3,6-dihydro-2h-pyridin-4-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]-4-(pentafluoro-$l^{6}-sulfanyl)benzamide Chemical compound C1=C(F)C=C(C=2C=3C=C(NC=3N=CN=2)C=2CCN(CC=2)C(=O)N2CCCC2)C(C)=C1NC(=O)C1=CC=C(S(F)(F)(F)(F)F)C=C1 SCGWVZNPYKESGN-UHFFFAOYSA-N 0.000 claims 1
- UJVGRWVBHNSHNC-UHFFFAOYSA-N n-[5-fluoro-3-[6-[1-(2-hydroxyacetyl)-3,6-dihydro-2h-pyridin-4-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-2-methylphenyl]-4-(pentafluoro-$l^{6}-sulfanyl)benzamide Chemical compound C1=C(F)C=C(C=2C=3C=C(NC=3N=CN=2)C=2CCN(CC=2)C(=O)CO)C(C)=C1NC(=O)C1=CC=C(S(F)(F)(F)(F)F)C=C1 UJVGRWVBHNSHNC-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- BCWWANOFSOIDRH-UHFFFAOYSA-N tert-butyl 4-[4-[3-[(4-tert-butylbenzoyl)amino]-2-[tert-butylsilyloxy(diphenyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC(=CC1)C1=CC2=C(N=CN=C2C2=C(C(=CC=C2)NC(C2=CC=C(C=C2)C(C)(C)C)=O)C(O[SiH2]C(C)(C)C)(C2=CC=CC=C2)C2=CC=CC=C2)N1 BCWWANOFSOIDRH-UHFFFAOYSA-N 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 description 8
- 208000034578 Multiple myelomas Diseases 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 208000003476 primary myelofibrosis Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000008601 Polycythemia Diseases 0.000 description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000005305 organ development Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505560P | 2011-07-08 | 2011-07-08 | |
| US61/505,560 | 2011-07-08 | ||
| PCT/IB2012/001699 WO2013008095A1 (en) | 2011-07-08 | 2012-07-07 | Novel pyrrolo pyrimidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014520793A JP2014520793A (ja) | 2014-08-25 |
| JP2014520793A5 true JP2014520793A5 (enExample) | 2017-06-08 |
| JP6145451B2 JP6145451B2 (ja) | 2017-06-14 |
Family
ID=46880751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517980A Expired - Fee Related JP6145451B2 (ja) | 2011-07-08 | 2012-07-07 | 新規なピロロピリミジン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9233111B2 (enExample) |
| EP (1) | EP2729466B1 (enExample) |
| JP (1) | JP6145451B2 (enExample) |
| KR (1) | KR20140058543A (enExample) |
| CN (1) | CN103732596B (enExample) |
| AU (1) | AU2012282229B2 (enExample) |
| BR (1) | BR112014000314A2 (enExample) |
| CA (1) | CA2841111A1 (enExample) |
| EA (1) | EA201490229A1 (enExample) |
| ES (1) | ES2548414T3 (enExample) |
| MX (1) | MX2014000338A (enExample) |
| WO (1) | WO2013008095A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103732596B (zh) | 2011-07-08 | 2016-06-01 | 诺华股份有限公司 | 吡咯并嘧啶衍生物 |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| CA2869954C (en) * | 2012-04-20 | 2023-01-03 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity |
| KR20150032340A (ko) | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
| SMT201700160T1 (it) | 2013-04-25 | 2017-05-08 | Beigene Ltd | Composti eterociclici fusi come inibitori di protein chinasi |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| US20150157634A1 (en) * | 2013-12-02 | 2015-06-11 | Pharmacyclics, Inc. | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| UA125061C2 (uk) * | 2014-10-06 | 2022-01-05 | Мерк Патент Ґмбг | Сполуки гетероарилу як інгібітори ткб і їх застосування |
| HUE050706T2 (hu) * | 2014-10-24 | 2020-12-28 | Bristol Myers Squibb Co | Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként |
| WO2016079669A1 (en) * | 2014-11-19 | 2016-05-26 | Novartis Ag | Labeled amino pyrimidine derivatives |
| AR102871A1 (es) * | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
| EP3042903B1 (en) | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060680T2 (hu) | 2015-11-19 | 2023-04-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| WO2017106634A1 (en) * | 2015-12-17 | 2017-06-22 | Incyte Corporation | N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators |
| EP3394033B1 (en) | 2015-12-22 | 2020-11-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| MD3472167T2 (ro) | 2016-06-20 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018033853A2 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46285A (fr) | 2016-09-19 | 2019-07-31 | Mei Pharma Inc | Polythérapie |
| KR102686957B1 (ko) * | 2016-11-08 | 2024-07-22 | 주식회사 대웅제약 | 신규한 피롤로피리미딘 유도체 및 이를 포함하는 약학적 조성물 |
| PE20200005A1 (es) | 2016-12-22 | 2020-01-06 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1 |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| MA47123A (fr) | 2016-12-22 | 2021-03-17 | Incyte Corp | Dérivés de benzooxazole en tant qu'mmunomodulateurs |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| WO2018145525A1 (zh) | 2017-02-08 | 2018-08-16 | 中国医药研究开发中心有限公司 | 吡咯并芳杂环类化合物及其制备方法和医药用途 |
| TW202515616A (zh) | 2017-06-26 | 2025-04-16 | 英屬開曼群島商百濟神州有限公司 | 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途 |
| CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| CN111936501B (zh) * | 2018-03-26 | 2023-09-22 | 诺华股份有限公司 | 布鲁顿酪氨酸激酶降解剂 |
| EP3774804A1 (en) * | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| PL4212529T3 (pl) | 2018-03-30 | 2025-07-07 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
| HRP20230306T1 (hr) | 2018-05-11 | 2023-05-12 | Incyte Corporation | Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori |
| WO2020249001A1 (zh) | 2019-06-10 | 2020-12-17 | 百济神州瑞士有限责任公司 | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| IL291471B2 (en) | 2019-09-30 | 2025-04-01 | Incyte Corp | Pyrimido[3,2–D]pyrimidine compounds as immunomodulators |
| CR20220237A (es) | 2019-11-11 | 2022-08-05 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
| CN111704617B (zh) * | 2020-06-15 | 2022-08-23 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| AR124001A1 (es) | 2020-11-06 | 2023-02-01 | Incyte Corp | Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| CN116782946A (zh) * | 2021-01-30 | 2023-09-19 | 百济神州有限公司 | 使用btk抑制剂治疗慢性活动性抗体介导的排斥的方法 |
| US20240216513A1 (en) | 2021-03-12 | 2024-07-04 | Novartis Ag | Fatty acid-bifunctional degrader conjugates and their methods of use |
| CN115073469B (zh) * | 2021-03-15 | 2023-12-22 | 药雅科技(上海)有限公司 | 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
| IL139811A0 (en) | 1998-06-04 | 2002-02-10 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| GB2345868A (en) | 1999-01-23 | 2000-07-26 | Martin Hodgson | Self adhesive magnetic or electromagnetic tapes |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| WO2002038797A2 (en) | 2000-10-23 | 2002-05-16 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase, their identification and use |
| PE20020544A1 (es) | 2000-11-07 | 2002-07-30 | Novartis Ag | Derivados de indolilmaleimida |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| AR039209A1 (es) | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
| EP2322203A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7365096B2 (en) | 2002-12-09 | 2008-04-29 | Board Of Regents, The University Of Texas System | Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3) |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
| AU2004251146A1 (en) | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| GB2432834A (en) | 2004-01-12 | 2007-06-06 | Cytopia Res Pty Ltd | Selective Kinase Inhibitors |
| PE20051092A1 (es) * | 2004-01-29 | 2006-01-20 | Novartis Ag | Derivados de pirrolo-pirimidina utiles para el tratamiento de enfermedades proliferativas |
| CA2575808A1 (en) | 2004-08-02 | 2006-02-16 | Osi Pharmaceuticals, Inc. | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| CA2601628C (en) | 2005-03-10 | 2014-05-13 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| BRPI0608513A2 (pt) | 2005-03-15 | 2010-01-05 | Irm Llc | compostos e composições como inibidores da proteìna quinase |
| CA2607299C (en) | 2005-05-13 | 2013-05-07 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
| NZ563774A (en) | 2005-05-20 | 2010-04-30 | Methylgene Inc | Inhibitors of VEGF receptor and HGF receptor signaling |
| JP2009531274A (ja) * | 2005-12-07 | 2009-09-03 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | キナーゼ阻害性ピロロピリジン化合物 |
| KR101391900B1 (ko) | 2005-12-13 | 2014-05-02 | 인사이트 코포레이션 | 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘 |
| WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
| EP1979353A2 (en) | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| US7678818B2 (en) | 2006-02-07 | 2010-03-16 | Hoffmann-La Roche Inc. | Anthranilamide and 2-amino-heteroarene-carboxamide compounds |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| ATE476418T1 (de) | 2006-06-08 | 2010-08-15 | Amgen Inc | Benzamidderivate und assoziierte verwendungen |
| DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| EP2068849A2 (en) | 2006-09-11 | 2009-06-17 | CGI Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
| EP2526934B1 (en) | 2006-09-22 | 2015-12-09 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| KR101791981B1 (ko) | 2007-03-14 | 2017-11-01 | 비온실 에스.알.엘. | 화학요법 약물-내성 상피성 종양을 치료하기 위한 ｓｉＲＮＡ-매개 유전자 침묵화 |
| SG10202107066WA (en) | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
| CA2701275C (en) | 2007-10-23 | 2016-06-21 | F. Hoffmann-La Roche Ag | Kinase inhibitors |
| US20090118276A1 (en) | 2007-11-02 | 2009-05-07 | Wyeth | Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors |
| CN101952283B (zh) | 2007-12-14 | 2013-04-17 | 霍夫曼-拉罗奇有限公司 | 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物 |
| US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PL2300459T3 (pl) | 2008-07-02 | 2013-10-31 | Hoffmann La Roche | Nowe fenylopirazynony jako inhibitory kinazy |
| MX2011000661A (es) | 2008-07-16 | 2011-05-25 | Pharmacyclics Inc | Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos. |
| AU2009291783A1 (en) | 2008-09-10 | 2010-03-18 | Alcon Research, Ltd | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| US20100261776A1 (en) | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
| WO2010068806A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
| WO2010117935A1 (en) | 2009-04-06 | 2010-10-14 | Schering Corporation | Compounds and methods for antiviral treatment |
| WO2010117936A1 (en) | 2009-04-06 | 2010-10-14 | Schering Corporation | Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent |
| JP5918693B2 (ja) | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| TWI711610B (zh) * | 2009-09-04 | 2020-12-01 | 美商百健Ｍａ公司 | 布魯頓氏酪胺酸激酶抑制劑 |
| EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYL-BTK INHIBITORS |
| JP2013526543A (ja) | 2010-05-12 | 2013-06-24 | アッヴィ・インコーポレイテッド | ピロロピリジン系およびピロロピリミジン系キナーゼ阻害薬 |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| EP2632898A4 (en) | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | HETEROCYCLIC TYROSINE KINASE HEMMER |
| US20130178483A1 (en) | 2011-06-28 | 2013-07-11 | Pharmacyclics, Inc. | Methods and Compositions for Inhibition of Bone Resorption |
| CN103732596B (zh) | 2011-07-08 | 2016-06-01 | 诺华股份有限公司 | 吡咯并嘧啶衍生物 |
| US9273317B2 (en) | 2011-08-09 | 2016-03-01 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of MYC-driven tumor cells |
| DE102011111400A1 (de) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| EP2771010A4 (en) | 2011-10-19 | 2015-04-01 | Pharmacyclics Inc | USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS |
| CN103974954B (zh) | 2011-11-14 | 2016-08-24 | 北京赛林泰医药技术有限公司 | 调节激酶的化合物、含有它们的组合物及其用途 |
-
2012
- 2012-07-07 CN CN201280033935.9A patent/CN103732596B/zh not_active Expired - Fee Related
- 2012-07-07 CA CA2841111A patent/CA2841111A1/en not_active Abandoned
- 2012-07-07 MX MX2014000338A patent/MX2014000338A/es unknown
- 2012-07-07 BR BR112014000314A patent/BR112014000314A2/pt not_active IP Right Cessation
- 2012-07-07 WO PCT/IB2012/001699 patent/WO2013008095A1/en not_active Ceased
- 2012-07-07 EP EP12761655.5A patent/EP2729466B1/en not_active Not-in-force
- 2012-07-07 EA EA201490229A patent/EA201490229A1/ru unknown
- 2012-07-07 ES ES12761655.5T patent/ES2548414T3/es active Active
- 2012-07-07 AU AU2012282229A patent/AU2012282229B2/en not_active Expired - Fee Related
- 2012-07-07 US US14/130,536 patent/US9233111B2/en not_active Expired - Fee Related
- 2012-07-07 KR KR1020147002986A patent/KR20140058543A/ko not_active Withdrawn
- 2012-07-07 JP JP2014517980A patent/JP6145451B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520793A5 (enExample) | ||
| JP6145451B2 (ja) | 新規なピロロピリミジン誘導体 | |
| JP6411342B2 (ja) | アミド化合物 | |
| JP6556146B2 (ja) | 複素環化合物 | |
| HRP20230585T1 (hr) | Novi derivati amino pirimidina | |
| JP6914933B2 (ja) | ヤヌスキナーゼ、並びにその組成物及びその使用 | |
| HRP20150173T1 (hr) | Oksazolom supstituirani indazoli kao inhibitori pi3-kinaze | |
| JP6868011B2 (ja) | ピラゾリル置換ヘテロアリール及び医薬としてのその使用 | |
| JP2018534326A5 (enExample) | ||
| JP2023523418A (ja) | Ｎｌｒｐ３の阻害剤としての三環式化合物 | |
| JP7197558B2 (ja) | Ａ２ａ阻害剤及び癌の治療に使用するための化合物としての２－オキソ－チアゾール誘導体 | |
| TW202102223A (zh) | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 | |
| KR20170016987A (ko) | 헤테로시클릭 화합물 및 이들의 레티노이드-관련 희귀 수용체 (ｒｏｒ) 감마-ｔ 저해제로서의 용도 | |
| JP7228318B6 (ja) | 処置用化合物及び組成物、並びにその使用方法 | |
| KR20160038008A (ko) | 브로모도메인 억제제로서 신규 퀴나졸리논 | |
| EP2863748A2 (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| MX2013001872A (es) | Inhibidores de oxadiazol de la produccion de leucotrieno. | |
| JP2025527640A (ja) | 新規ｎｌｒｐ３インフラマソーム阻害剤 | |
| Focken et al. | Design of conformationally constrained acyl sulfonamide isosteres: identification of N-([1, 2, 4] triazolo [4, 3-a] pyridin-3-yl) methane-sulfonamides as potent and selective h NaV1. 7 inhibitors for the treatment of pain | |
| JP6477484B2 (ja) | 含硫黄二環式化合物 | |
| JP2014516059A (ja) | 新規Ｓｙｋ阻害剤としての置換ピリドピラジン | |
| JP2018199623A (ja) | 含窒素縮合複素環化合物 | |
| CN117279899A (zh) | 作为nlrp3炎性小体抑制剂的酞嗪酮衍生物 | |
| EP4568975A1 (en) | Heterocyclic compound | |
| WO2024214046A1 (en) | Pyrazolopyrimidine derivatives as inhibitors of nlrp3 |